<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma <z:chebi fb="0" ids="16247">phospholipid</z:chebi> transfer protein (PLTP) plays an important role in <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>PLTP activity is elevated in patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, a condition with strongly elevated risk for <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to test the hypothesis that <z:chebi fb="0" ids="35664">statins</z:chebi> reduce PLTP activity and to examine the potential role of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E (apoE) </plain></SENT>
<SENT sid="3" pm="."><plain>PLTP activity and apoE were measured in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> from the DALI (<z:mp ids='MP_0002055'>Diabetes</z:mp> <z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> <z:chebi fb="23" ids="18059">Lipid</z:chebi> Intervention) Study, a 30-week randomized double-blind placebo-controlled trial with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (10 and 80 mg daily) </plain></SENT>
<SENT sid="4" pm="."><plain>At baseline, PLTP activity was positively correlated with waist circumference, HbA(1c), <z:chebi fb="105" ids="17234">glucose</z:chebi>, and apoE (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> treatment resulted in decreased PLTP activity (10 mg <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>: -8.3%, P &lt; 0.05; 80 mg <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>: -12.1%, P &lt; 0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>Plasma apoE decreased by 28 and 36%, respectively (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>The decrease in apoE was strongly related to the decrease in PLTP activity (r = 0.565, P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>The change in apoE remained the sole determinant of the change in PLTP activity in a multivariate model </plain></SENT>
<SENT sid="9" pm="."><plain>The activity of PLTP in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is decreased by <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>The association between the decrease in PLTP activity and apoE during <z:chebi fb="0" ids="35664">statin</z:chebi> treatment supports the hypothesis that apoE may prevent PLTP inactivation </plain></SENT>
</text></document>